Literature DB >> 22245529

Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support.

Lawrence Engmann1, Claudio Benadiva.   

Abstract

Although gonadotropin-releasing hormone agonist (GnRHa) trigger is effective in the prevention of ovarian hyperstimulation syndrome, lower conception rates have been reported. Intensive luteal phase support is an effective approach to improve implantation rates in women with peak E(2) levels ≥ 4,000 pg/mL. However, patients with peak E(2) levels <4,000 pg/mL may require a dual trigger with GnRHa and 1,000 IU hCG and intensive luteal phase support to improve implantation rates.
Copyright © 2012 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22245529     DOI： 10.1016/j.fertnstert.2011.12.020

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  9 in total

1.  GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.

Authors:  Yannis Prapas; Konstantinos Ravanos; Stamatios Petousis; Yannis Panagiotidis; Achilleas Papatheodorou; Chrysoula Margioula-Siarkou; Assunta Iuliano; Giuseppe Gullo; Nikos Prapas
Journal:  J Assist Reprod Genet       Date:  2017-08-03       Impact factor: 3.412

2.  Has ART Finally Got a Patient-Friendly Progesterone?

Authors:  Gautam N Allahbadia
Journal:  J Obstet Gynaecol India       Date:  2015-10

3.  Impact of elevated peak serum estradiol levels during controlled ovarian hyperstimulation on the birth weight of term singletons from fresh IVF-ET cycles.

Authors:  Nigel Pereira; David E Reichman; Dan E Goldschlag; Jovana P Lekovich; Zev Rosenwaks
Journal:  J Assist Reprod Genet       Date:  2015-02-15       Impact factor: 3.412

4.  Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series.

Authors:  Bülent Gülekli; Funda Göde; Zerrin Sertkaya; Ahmet Zeki Işık
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

5.  Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition.

Authors:  Samuel Santos-Ribeiro; Nikolaos P Polyzos; Katrien Stouffs; Michel De Vos; Sara Seneca; Herman Tournaye; Christophe Blockeel
Journal:  J Assist Reprod Genet       Date:  2015-05-17       Impact factor: 3.412

Review 6.  Pharmaceutical options for triggering of final oocyte maturation in ART.

Authors:  Juan Carlos Castillo; Peter Humaidan; Rafael Bernabéu
Journal:  Biomed Res Int       Date:  2014-07-15       Impact factor: 3.411

Review 7.  Gonadotropin-releasing hormone agonist triggering of oocyte maturation in assisted reproductive technology cycles.

Authors:  Engin Türkgeldi; Lale Türkgeldi; Ayşe Seyhan; Barış Ata
Journal:  Turk J Obstet Gynecol       Date:  2015-06-15

8.  Gonadotropin-Releasing Hormone Agonist Versus Recombinant Human Chorionic Gonadotropin Triggering in Fertility Preservation Cycles.

Authors:  Einat Haikin Herzberger; Sabaa Knaneh; Hadar Amir; Adi Reches; Dalit Ben-Yosef; Yael Kalma; Foad Azem; Nivin Samara
Journal:  Reprod Sci       Date:  2021-06-02       Impact factor: 3.060

Review 9.  Optimal usage of the GnRH antagonists: a review of the literature.

Authors:  Alan B Copperman; Claudio Benadiva
Journal:  Reprod Biol Endocrinol       Date:  2013-03-15       Impact factor: 5.211
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.